RxDoctor Payments Data

John Cooke

Cardiovascular Disease · Stanford, CANPI 1902932155

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,000 of the $1,234 with a category attached, or 81.1%. Pfizer accounts for 81.1% of it on its own, with 2 other manufacturers making up the rest. That places this record below the midpoint for cardiovascular disease clinicians in CA, where the typical reported total is $2,142.

$1,234in general payments, 2019–2025

Across 5 payments — averaging $246.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • Biotronik Inc.$117
  • AbbVie$117
$1,227,974in research payments, 2019–2025

Across 3 payments — averaging $409,325 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Avita Medical Americas, LLC$1.2M

What the payments were for

  • Consulting fees$1,00081%
  • Food & beverage$23419%

General payments by program year

19
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer1$1,000
Biotronik Inc.3$117
AbbVie1$117

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,234 in reported general payments places this provider in the 40th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California →

Other cardiovascular disease in Stanford

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →